Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
AstraZeneca
Baxter
Boehringer Ingelheim
McKinsey
UBS
Cipla
Daiichi Sankyo
Healthtrust
Federal Trade Commission

Generated: October 19, 2017

DrugPatentWatch Database Preview

KENACORT Drug Profile

« Back to Dashboard

Which patents cover Kenacort, and when can generic versions of Kenacort launch?

Kenacort is a drug marketed by Delcor Asset Corp and is included in two NDAs.

The generic ingredient in KENACORT is triamcinolone. There are fifty-one drug master file entries for this compound. Additional details are available on the triamcinolone profile page.

Summary for Tradename: KENACORT

US Patents:0
Applicants:1
NDAs:2
Bulk Api Vendors: see list40
Clinical Trials: see list2
Patent Applications: see list6,974
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:KENACORT at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Delcor Asset Corp
KENACORT
triamcinolone diacetate
SYRUP;ORAL012515-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Delcor Asset Corp
KENACORT
triamcinolone
TABLET;ORAL011283-006Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Delcor Asset Corp
KENACORT
triamcinolone
TABLET;ORAL011283-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Delcor Asset Corp
KENACORT
triamcinolone
TABLET;ORAL011283-008Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Delcor Asset Corp
KENACORT
triamcinolone
TABLET;ORAL011283-010Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Cantor Fitzgerald
Moodys
UBS
QuintilesIMS
Accenture
Cerilliant
Merck
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot